Belimumab to help highly sensitized kidney transplant candidates
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Be a candidate for kidney transplantation
- Be highly sensitized, meaning very few donor organs would match you
- Not be pregnant or breastfeeding, or agree to use effective contraception during the study
- Not have received certain immune-suppressing medications in the past year
- Not have active infections or serious immune system problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.